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ABSTRACT
Improvements in adult cancer survivorship can be achieved frombehavioral changes and adopting screening pro-
grams. Yet, these approaches cannot be readily applied to lower themorbidity andmortality from childhood can-
cers. Rather, pediatric oncologists must rely on procedures and therapies to treat, rather than prevent
malignancies. The systematic application of chemotherapy, radiation therapy, and surgery has led to remarkable
advances in survival but these improvements have come at a cost. Children routinely receive chemotherapy
agents that were designed decades ago, and these drugs have predictable side effects that result in the loss of po-
tential for long-term survivors. The advent of targeted applications of immune-based therapies offers children
with cancer a new class of oncolytic therapies that may be used to treat disease refractory to conventional ap-
proaches and lessen the toxicity of current treatment regimens without compromising remission. This review
explores how 3 components of the immune system—T cells, natural killer (NK) cells, and antibodies—can be
used for therapy of pediatric malignancies.
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hood cancer that range from being considered as stan-
dard practice and widely applied, to experimental and
only available at specialized centers. Examples of read-
ily available immunotherapies that have entered into
clinical practice include a commercially available vac-
cine for the prevention of human papillomavirus
(HPV) infection and associated cancers, and therapeu-
tic monoclonal antibodies (mAbs) targeting CD20 to
help treat lymphomas. The experimental immunother-
apies for pediatric malignancies encompass all aspects
of the immune system. Investigators have tested vac-
cines, infused antigen-specific T cells, and genetically
modified T cells rendered specific for antigen, adop-
tively transferred NK cells, and administered exoge-
nous cytokines. In this review, Dr. Grupp discusses
how the adaptive immune system can be manipulated
for the treatment of neuroblastoma (NBL). Dr. Verne-
ris then shows how the innate immune system can be
manipulated for the treatment of pediatric neoplasms.
Finally, Dr. Sondel demonstrates how mAb, and in par-
ticular antibody-cytokine fusions, can be used to treat
childhood cancer. These are 3 examples from a long
list of potential immunotherapies, as many investiga-tors have developed and are testing new immune-based
treatments for pediatric malignancies.
CELL THERAPY FOR NEUROBLASTOMA
NBL is the second most common solid malignancy
of childhood (after CNS tumors). Although NBL has
a broad spectrum of clinical presentations and behavior,
high-risk NBL is still difficult to cure [1]. Some prog-
ress in treating high-risk NBL has correlated with esca-
lation of therapeutic intensity [2], although even with
an apparent complete remission following maximal-in-
tensity induction therapy, long-term event-free survival
(EFS) with standard treatment stubbornly remains less
than 40%. In this section, we describe several cell ther-
apy-based trials and possible future approaches for pa-
tients with this disease. We will begin with the current
standard (stem cell support for high-dose chemother-
apy), and move to T cell-based immunotherapy.
INFUSION OF AUTOLOGOUS HEMATOPOIETIC STEM
CELLS (HSCS) FOR NBL
HSCs capable of reestablishing tri-lineage hema-
topoiesis can be acquired from the bone marrow,33
34 S. A. Grupp et al.but in the setting of autologous transplantation, the
source of HSC has moved to collection of mobilized
peripheral blood stem cells (PBSC). The harvest and
storage of a patient’s own HSC followed by reinfu-
sion of those cells after high-dose (generally myeloa-
blative) chemotherapy is commonly referred to as
autologous hematopoietic stem-cell transplantation
(HSCT). A child presenting with high-risk NBL is
generally considered a good candidate for autologous
HSCT. Generally, NBL at presentation is a chemo-
therapy sensitive disease. Although most patients
can achieve a complete or partial remission with in-
duction chemotherapy, a high response rate does
not translate into a high EFS rate; 80% to 85% of pa-
tients have initially chemotherapy-responsive disease,
but less than 20% are long-term survivors with con-
ventional chemotherapy.
The study that defined autologous HSCT as
standard of care for high-risk NBL was Children’s
Cancer Group 3891. Patients were randomized to
a consolidation regimen with autologous HSCT
(supported by purged bone marrow) versus continu-
ation chemotherapy [3]. This study found that EFS
was improved in the group that received autologous
HSCT. In the initial report, the authors estimated
a 3.7-year EFS of 38% from diagnosis in those pa-
tients who underwent autologous HSCT followed
by the differentiation agent isotretinoin. An impor-
tant further innovation in the use of HSC therapies
for NBL was the switch to PBSC from marrow.
The more rapid recovery afforded by PBSC has de-
creased the risk of HSCT, and allowed the concept
of autologous HSCT to be extended to sequential
cycles. This ‘‘tandem transplantation’’ approach is
based on the hypothesis that further dose intensity
in this setting may result in improved outcome. Sev-
eral groups have tested tandem HSCT with promis-
ing results in pilot and phase II studies [4-6]. We
have concluded the largest of these studies, con-
ducted over 6 years at 4 cooperating institutions
and observed a 3-year EFS of 55% in a sequentially
treated group of 97 patients (Figure 1). The study
was designed around early collection of PBSC,
the use of CD34 selection as a method to purge
NBL cells from the PBSC products, and 2 nonover-
lapping myeloablative consolidation regimens.
There were 3 cases of EBV lymphoproliferative dis-
ease (EBV-LPD) seen among patients treated in this
fashion. EBV-LPD is uncommon following autolo-
gous HSCT, and the Mackall group has suggested
that T-cell depletion that results from CD34 selec-
tion may not increase immunosuppression [7,8]. Our
study experience would suggest that the combina-
tion of the use of a CD34-selected PBSC product
and tandem transplant is more immunosup-
pressive than autologous HSCT using unpurged
PBSC [9,10].T CELL AUGMENTATION FOR NBL
The issue of immunosuppression induced by au-
tologous HSCT is important when considering alter-
native approaches to treating high-risk NBL.
Although there is some suggestion that tandem
HSCT may improve outcome in these patients, it is
indisputable that we have reached the limit of dose es-
calation. An alternative approach is required. T cell-
based therapies, possibly paired with a cancer vaccine,
represent a major area to explore novel treatments
[11,12]. However, T cells that may have antitumor ef-
ficacy, may not be well-suited to treating bulky disease,
and thus might be most efficacious if infused at the
point of minimal residual disease (MRD). This is the
point reached after chemotherapy, surgery, radiation,
and HSCT for NBL. Immunotherapy and/or tumor
Figure 1.Kaplan-Meier curves showing the overall and event-free sur-
vival (OS, EFS) for patients undergoing tandem autologous HSCT for
high-risk NBL. The patients received carboplatin/etoposide/cyclo-
phosphamide for the first HSCT, and melphalan/TBI for the second.
(A) Overall survival (OS) from diagnosis. (B) EFS from diagnosis.
Immunotherapy for Pediatric Cancer 35vaccines should probably be deployed as quickly as
possible after completion of conventional therapy,
but this is also a point where numbers of T cells and
associated effector function are minimal to absent.
One solution to this problem is to provide T cells to
the patient in an attempt to speed immunologic recov-
ery. This also has the potential to harness a profoundly
lymphopenic environment supportive of homeostatic
expansion. Unfortunately, the passenger T cells pro-
vided with a PBSC product, although large in number,
do not provide this solution, as recovery of cellular im-
munity after standard autologous PBSC transplant
(PBSCT) takes many months.
We have recently tested an alternative approach in
studies at the University of Pennsylvania and Chil-
dren’s Hospital of Philadelphia (CHOP). The cell
product utilized in all of these studies is ex vivo-
activated and expanded autologous T cells, using an
artificial ‘‘antigen-presenting cell’’ of anti-CD3 and
anti-CD28 activating antibodies coupled to beads
[13]. The cell manufacturing process operating in
compliance with current good manufacturing prac-
tices (GMP) produces a highly activated polyclonal
T cell population, containing numerically expanded
T cells that reflect the full repertoire of the cells input
into the culture [14,15]. We have referred to the infu-
sion of these activated T cells into lymphodepleted
patients as T cell augmentation (TCA). We have
completed a phase I trial of TCA in adult and pediatric
patients with high-risk lymphoma following autolo-
gous CD34-selected PBSC transplantation [16], dem-
onstrating promising normalization of lymphocyte
counts. In many cases, an absolute lymphocytosis was
observed following TCA, suggesting that homeostatic
T cell proliferation was induced.
In ongoing studies at CHOP, we have tested TCA
in patients with high-risk NBL. In a series of studies, we
are assessing the impact of TCA on immune reconsti-
tution in profoundly immunodeficient patients after
autologous HSCT. These patients are an informative
group to study TCA, as the need for HSCT is known
at diagnosis and T cells may thus be collected prior to
immunosuppressive chemotherapy. Some of our pre-
liminary data are presented in Figure 2. Patients receiv-
ing a CD34-selected PBSC product have slow recovery
of CD41 T cells, which is significantly and strikingly
improved after TCA given on day 112 after PBSC
infusion. Interestingly, CD4 recovery is even more
rapid when the infusion time is moved to day 12, with
above-normal lymphocyte and T cell counts apparent
as soon at 10 days after TCA. Among patients receiving
TCA day 12 after PBSC infusion, we have observed
lymphocyte counts by day 12 as high at 10,000/mL.
Four of these patients experienced an engraftment
syndrome clinically indistinguishable from autologous
graft-versus-host-disease (GVHD), with fever, a rash
characteristic of GVHD, and, in the 2 cases whereskin biopsies were performed, the pathology was
consistent with GVHD. In the current study, we are
assessing the impact of TCA on response to 2 vac-
cines— Prevnar conjugate vaccine and influenza vac-
cine. Preliminary analysis of the patients receiving
Prevnar on day 112 after autologous HSCT shows
protective antipneuomoccal antibody titers to multiple
serotypes as early as day 130 (S. Grupp, unpublished
data), which supports the hypothesis that TCA could
be used to support an anticancer immunization strat-
egy early after SCT and achievement of MRD. Similar
results in patients with myeloma receiving TCA and
Prevnar vaccination have recently been published by
Carl June and coworkers [17].
A possible target for a therapeutic cancer vaccine
could be the cancer antigen survivin. Survivin is ex-
pressed in NBL, with expression correlating with
adverse outcome [18,19]. In our studies, we have
observed high expression of survivin in all tested tumor
biopsies from high-risk NBL patients [20]. Impor-
tantly, we have found that most HLA-A21 patients
with NBL have survivin-specific T cells as identified
by tetramer-binding. These T cells might be expanded
and to kill both allogeneic and autologous NBL in the
appropriate HLA context. Support for this experimen-
tal design is provided by data demonstrating that when
whole NBL RNA is transfected into antigen-present-
ing cells (APC) and these cells are used to expand T
cells with specificity for NBL, the immunodominant
epitope in the effector T cell response is survivin
[20]. The Vonderheide group at the University of
Pennsylvania is currently testing a multicomponent
cancer vaccine containing survivin peptide in adult
cancer patients. This leads to a potential study design
where T cells are collected at diagnosis in NBL
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Figure 2. T cell recovery as assessed by peripheral blood CD41 T
cell count at indicated times after tandem autologous HSCT. The
groups include: patients receiving PBSC (no T cells), patients receiv-
ing T cell augmentation at day 112 and day 12 after the second
PBSC infusion, and 4 patients from the day 12 group who experi-
enced engraftment syndrome (Eng Synd).
36 S. A. Grupp et al.patients, undergo costimulated expansion and infusion
on day 12, followed by a survivin-derived peptide-
based cancer vaccine. All components necessary for
such a study, including GMP cell manufacturing,
a clinical grade vaccine, and sophisticated immunoas-
sessment tools, are currently available.
DONOR-DERIVED NATURAL KILLER (NK) CELLS FOR
IMMUNOTHERAPY OF TUMORS
NK cells are some of the earliest lymphocytes to
recover after allogeneic HSCT. These innate immune
effector cells recognize targets using cell-surface re-
ceptors that either positively or negatively modulate
activation. Using these receptors, NK cells can detect
and kill cells that have undergone viral infection or ma-
lignant transformation. NK cells also use these recep-
tors to interact with APC. Paradoxically, after
allogeneic HSCT they can either kill recipient APC
that trigger graft-versus-host disease (GVHD) or
NK cells can be activated by APC [21,22]. Following
activation, NK cells rapidly produce IFN-g, TNF-a,
and granulocyte macrophage–colony-stimulating
factor (GM-CSF), which can feed back to recruit and
activate other components of the immune system.
Considering these attributes, methods to improve
donor-derived NK cell numbers and/or function after
allogeneic HSCT may have significant impact.
High numbers of NK cells in allogeneic hemato-
poietic cell grafts are associated with improved trans-
plant-associated outcomes. Recipients of allo-grafts
with high NK cell content have significantly faster
neutrophil recovery [23-25], a lower incidence of non-
relapse mortality (NRM) [25,26], a reduction in both
bacterial and viral infections, faster immune reconsti-
tution [25], and less acute GVHD (aGVHD) [27]
and chronic GVHD (cGVHD) [24,26]. Numerous
studies show that NK cells recover early after alloge-
neic HSCT, regardless of hematopoietic cell source
and/or graft manipulation such as T cell depletion
(TCD) [28-30]. Although all patients show this rapid
recovery, those with high numbers of NK cells in the
peripheral circulation early after transplant (day
130) experience less NRM, aGVHD, acute myeloge-
nous leukemia (AML) (but not adult acute lympho-
blastic leukemia (ALL)) relapse, compared to
patients with low NK cell numbers at day 130 [31].
NK CELL RECEPTORS AND THEIR FUNCTION
NK cells express a multitude of receptors that dic-
tate whether they mediate cytotoxicity and/or cytokine
secretion following contact with either tumor cells or
allogeneic APC. These receptors can be functionally
grouped into activating or inhibitory receptors (re-
viewed in [32] and [33]). The two best-characterized
NK inhibitory receptors are the killer immunoglo-
bulin receptors (KIR) and the heterodimeric complexbetween CD94 and NKG2A (CD94/NKG2A).
Individuals can express up to 15 different KIR genes
that recognize conserved determinates on HLA-A, -B,
and -C [34]. In contrast, CD94/NKG2A recognizes
HLA-E, which shows limited polymorphism [35]. As
shown in Figure 3, binding of these inhibitory recep-
tors with their respective ligands results in strong
NK cell inhibition, whereas the lack of engagement
of these receptors may allow target killing. Such a situ-
ation can occur if MHC class I is downregulated (asso-
ciated with malignant transformation [36]) or after
allogeneic transplant where donor NK cells may
express a KIR that cannot recognize host major histo-
compatibility complex (MHC) (ie, KIR-ligand mis-
match, Figure 3d and e, respectively) [37].
Individual NK cells can display a varying number
of inhibitory receptors on their surface that further
NK cell AML blast Outcome
No kill
CD94/NKG2A: HLA-E
A
Kill
CD94/NKG2A: nothing
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KIR:self-MHC
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Figure 3. Possible outcomes following NK-Cell inhibitory receptor
interaction with target cells such as AML blasts. (A) Engagement of
CD94/NKG2A with nonpolymorphic HLA-E (limited polymor-
phism) results in no killing; (B) lack of HAL-E expression on leuke-
mia cells prevents CD94/NKG2A signaling, creating a situation
where NK cells may not be inhibited; (C) KIR binding to self-
HLA-A, or -B, or -C on leukemia cells results in NK inhibition;
(D) a lack of HLA-A, -B, or -C on leukemia cells results in no KIR
engagement and enhanced NK-cell killing, and (E) KIR that do
not recognize HLA-A, -B, and -C on leukemia cells (as in the setting
of KIR-ligand mismatched transplant) can result in increased killing.
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shown in Figure 4, most peripheral blood (PB)-derived
NK cells will express CD94/NKG2A, either alone or
in combination with KIR (right upper and lower quad-
rants). A small subset of NK cells will display KIR, but
not CD94/NKG2A (Figure 4, upper left). Still another
subset lacks both KIR and CD94/NKG2A (Figure 4,
lower left quadrant). This constellation of expression
of inhibitory receptors by individual NK cells creates
a heterogeneous populations, each with differing abil-
ity to recognize subtle changes in MHC class I on tar-
get cells.
The ligand for CD94/NKG2A, HLA-E shows
limited polymorphism and thus, does not vary between
individuals. Accordingly, NK cells that express CD94/
NKG2A (either alone or in combination with KIR) are
expected to be inhibited equally by donor or recipient
HLA-E. In contrast, the ligands for KIR are determi-
nants of HLA-A, -B, and -C. Such determinants are
polymorphic and can vary between individuals. Fol-
lowing HLA mismatched transplantation there is
a possibility that the KIR present on donor NK cells
will not recognize HLA on recipient leukemia
(Figure 3e, ‘‘KIR-ligand mismatch’’). If such a situation
occurs, the NK cells that express only KIR (and not
CD94/NKG2A) are expected to mediate maximal
graft-versus-leukemia (GVL) effects because they are
not restrained by either inhibitory receptor. Such
NK cells have been referred to as ‘‘alloreactive NK
Figure 4. Individual NK-cells differ in inhibitory receptor expres-
sion. Shown is a FACS plot of peripheral blood NK cells (gated on
CD561CD32) from a healthy donor. Four distinct populations of
cells can be identified by staining for KIR cocktail (CD158a,
CD158b, and CD158e) vs CD94. The majority of NK cells express
CD94 (and NKG2A, not shown) and are inhibited by HLA-E (right
upper and lower quadrant). A small fraction of cells express KIR, but
not CD94 (left upper quadrant), and these cells have the potential to
be "alloreactive." The KIRnegCD94neg fraction is hyporesponsive.cells.’’ These cells typically make up a small fraction
of PB NK cells in normal donors (Figure 4, upper
left). Likewise, shortly after transplant KIR1CD94/
NKG2Aneg NK cells are quite rare and increase over
time [38]. Last, the NK cell subset that lacks all inhib-
itory receptors (KIRnegCD94/NKG2Aneg; Figure 4,
lower left) is hyporesponsive and shows limited cyto-
kine secretion and cytotoxicity. To date, it is not clear
whether such cells are developmental precursors or
functionally hyporesponsive [39-41].
For NK cells to fully mediate a GVL effect, NK
cell activating receptors also need to be engaged.
Such activating receptors include NKG2D, DNAM-
1, and the natural cytotoxicity receptors (NKp30,
NKp44, and NKp46) [33]. To date, less is known
about the receptors that activate human NK cells
than the inhibitory receptors. The ligands for some
of these receptors have been identified. Examination
of leukemia cell lines and freshly isolated patient sam-
ples show that the ligands for NK activating receptors
are expressed. Some data also support the concept that
these ligands are more abundant on AML blasts (rela-
tive to ALL blasts) [42], which may confirm the clinical
observations that NK alloreacitivity may be more pow-
erful in the myeloigenous leukemia setting [37].
STRATEGIES TO ENHANCE NK CELL FUNCTION AFTER
ALLOGENEIC HSCT
Whether NK cells are fully functional after alloge-
neic HSCT is not entirely clear. A number of factors
may impact NK cell immunobiology including condi-
tioning regimens (ie, presence of ATG or campath
H1), GVHD prophylaxis (and treatment), donor cell
source, and viral reactivation. However, even within
the same regimen, differences have been noted. For in-
stance, early after allogeneic HSCT, Ruggeri et al. [37]
could generate functional, alloreactive NK cell clones
from recipients. In contrast, Nguyen et al. [43] found
that NK cells recovering early showed poor cytotoxic-
ity. In the above studies, no GVHD prophylaxis was
used. However, immune suppressive agents are admin-
istered to most patients after HSCT in which the allo-
graft is not manipulated and the impact of these
medications on NK cell function is just now being un-
derstood. Wang et al. [44] recently showed that culture
of NK cells with physiologic levels of cyclosporine A
(CSA) results in impaired proliferation of the
CD561CD161KIR2 NK cell subset, whereas the
CD561CD16negKIRneg cells were less effected. Inter-
estingly, this latter subset is also present at higher
numbers early after HSCT, suggesting that CSA may
play account for this. Exposure to CSA did not impair
cytotoxicity against leukemia cell lines. In contrast,
following corticosteroid treatment for GVHD, patient
NK cells showed less activating receptor expression
38 S. A. Grupp et al.(NKp30 and NKp46), and this correlated with a reduc-
tion in cytotoxicity [45].
As described above, large numbers of NK cells in
the graft or rapid NK cell recovery are associated
with improved outcomes. Thus, strategies to enhance
NK cell recovery after allogeneic HSCT may be indi-
cated. Although exogenous IL-2 can increase PB-de-
rived NK cells after autologous transplant [46], it
may also increase regulatory T cells [47,48], which
could negatively modulate the GVL effect. Accord-
ingly, some studies have failed to show increased NK
cell killing when posttransplant IL-2 is used [46].
Other cytokines, such as IL-12, IL-15, IL-18, and
IL-21, all positively modulate NK cell function, but
may also exacerbate GVHD. To date, none have
been administered after allogeneic HSCT.
Increasing NK cell numbers could also be achieved
by donor leukophoresis, followed by TCD, in vitro ac-
tivation with IL-2, and adoptive transfer. Such studies
show that haploidentical NK cell infusions can be
safely administered to patients without GVHD and
in some chemotherapy refractory AML patients, he-
matologic remissions could be achieved [49].
Other approaches may include the use of pharma-
cologic agents to ‘‘sensitize’’ leukemia to NK cell at-
tack. Recently, Rohner [50] has shown that a cocktail
of differentiation agents (5-aza-2’-deoxycytidine, tri-
chostatin A, vitamin D3, bryostatin-1) increases
NKG2D ligand expression on AML cell lines. Simi-
larly, using the HDAC inhibitor trichostatin, Kato
et al. [51] could increase NK killing of patient-derived
ALL blasts by increasing NKG2D ligand expression.
Other ‘‘off-the-shelf’’ approaches may include use of
mAb to block NK cell inhibitory receptor (KIR or
CD94/NKG2A) signaling. Such antibodies against
CD94 or KIR have been shown to enhance in vitro cy-
totoxicity against HLA expressing targets [52,53], such
as ALL cell lines.
ANTIBODY FOR IMMUNOTHERAPY OF TUMOR
Since the original description of antibodies poten-
tially functioning as ‘‘magic bullets’’ by Paul Erlich at
the turn of the last century, immunologists have
sought ways to utilize the immune system and particu-
larly antibodies as selective antitumor therapeutics.
Not until 1975, when Kohler and Milstein described
the technology for production of monoclonal, mono-
specific antibodies, was the technology available to po-
tentially realize Erlich’s dream in the setting of cancer
treatment. Initial efforts to immunize mice with hu-
man tumors to generate tumor-specific mAbs resulted
in a myriad of antibodies that recognized species spe-
cific antigenic determinants expressed both on tumors
and normal cells. Many of these target antigens are tis-
sue specific, and have been of great help in identifying
important structures on the surfaces of normal humancells. This has included characterization of numerous
normal membrane components of distinct subsets of
immune cells based on the initial distinction of the
‘‘T4’’ (now CD4) and T8 (now CD8) determinants
on helper versus cytotoxic T cells. With diligent
screening, a somewhat small set of target antigens rec-
ognizable by mouse antibodies were identified that
were either specific to tumors of certain histology, or
were highly overexpressed by certain tumors and ex-
pressed at low levels on most normal tissues or only
on a small subset of potentially ‘‘expendable’’ normal
tissues. The underlying principle of utilizing such re-
agents for therapy is based on the selective recognition
of tumor cells by tumor reactive monoclonals but not
of most normal cells by the putative therapeutic anti-
body [54-58].
Initial antigens of interest that were described in-
cluded the CD10, CD20, CD19, and CD5 molecules
expressed on subsets of human B and T cells, including
leukemic cells, the GD2 molecule on NBL and mela-
noma, as well as molecules expressed on malignancies
more common in adults such as HER-2 seen in breast
cancers and the epithelial cell adhesion molecule (EP-
CAM) seen on adult epithelial cancers.
Although the above targets (and several more) have
been used in clinical testing for cancer treatment, a va-
riety of other mAbs have also been tested, but not
themselves as ‘‘anticancer therapeutics.’’ This category
includes the battery of ‘‘immunosuppressive’’ mAbs
that have been used in several clinical settings of auto-
immune disease and to prevent graft rejection or
GVHD, particularly in the setting of allogeneic
HSCT. These include mAbs against distinct lymphoid
subsets or against triggering receptors on the surface of
allo-activated lymphocytes (such as the IL-2 receptor).
ANTIBODY ENGINEERING
Once the genes for mAbs were cloned and placed
in expression plasmids, it was possible to genetically
engineer these genes for therapeutic purposes
[57,59,60]. This has included grafting the variable re-
gions of mouse immunoglobulin genes onto the con-
stant regions of human immunoglobulin genes to
create ‘‘chimeric’’ mAbs. When the small complemen-
tarity determining region (CDR) of the murine anti-
bodies (which determines antigen binding) are
grafted into the appropriate CDR locations of human
immunoglobulin genes, the resulting protein is a ‘‘hu-
manized’’ antibody. Such chimeric or humanized anti-
bodies should be recognized as less ‘‘foreign’’ to the
human immune system and thus be neutralized less ac-
tively. In addition, modification of the Fc region of the
immunoglobulin molecule either through amino acid
substitution or by modifying the glycosylation can
influence the effector functions of the antibody. Fi-
nally, genetic manipulation can graft entirely distinct
Immunotherapy for Pediatric Cancer 39molecules onto immunoglobulins to provide fusion
proteins with multiple specificities and functions (see
below).
MECHANISMS OF ACTION OF TUMOR-REACTIVE MAB
THERAPEUTICS
mAbs that recognize targets selectively expressed
on tumors may have antitumor effects through a variety
of mechanisms. First is activation of the complement
cascade, which results in membrane damage and os-
motic lysis to the target cell. Second involves activation
of antibody dependent cellular cytotoxicity (ADCC).
This involves activation of effector cells (normally
NK cells, neutrophils, or monocytes/macrophages)
that express activating Fc receptors [61,62]. Once the
mAb forms multipoint binding to the target antigen
on the tumor cells, the Fc receptor lattice on the effec-
tor cells recognizes the pattern of expressed immuno-
globulins on the tumor cell and results in effector cell
activation and the destruction of target cells by molec-
ular pathways distinct for NK cells (granzyme, per-
forin, and/or Fas ligand) or for neutrophils and
macrophagesmonocytes (reactive oxygen species, ni-
tric oxide, tumor necrosis factor, and other pathways)
[63-65]. mAb can also cause direct antitumor effects
by binding to and ‘‘blocking’’ growth factor receptors
expressed on tumor cells, provided that these anti-
bodies bind to the receptor without activating it (in-
hibitory/antagonistic mAbs). For example, antibodies
to the epidermal growth factor receptor (EGFR) block
its ability to be stimulated by its selective ligand
(EGF), resulting in tumor growth inhibition. In addi-
tion, some agonistic mAbs bind to cell membrane re-
ceptors and transmit an active signal. If the
membrane receptor that is recognized is a ‘‘death re-
ceptor’’ such as Fas, the antibody can result in cell
death. Although this has theoretic implications, most
such antibodies do not show tumor specificity.
Of the panel of tumor reactive mAbs that have had
clinical testing and activity, a few have been FDA ap-
proved for general clinical use [54,55]. The mAb
against the CD20 determinant on B cells and their pre-
cursors (Rituximab) has demonstrated greatest efficacy
and is in the widest clinical use [66,67]. Although this
mAb may have some signaling capabilities against B
cells, and can also mediate complement dependent
killing (CDC), it seems that its in vivo effect is most
largely mediated through ADCC. This was demon-
strated by independent clinical studies evaluating the
Fc receptor polymorphisms associated with antitumor
activity. Patients that have inherited an NK cell recep-
tor phenotype or a neutrophil/monocyte receptor phe-
notype for their Fc receptors associated with high
affinity binding to the Rituximab IgG show a far
greater likelihood of antitumor effects in vivo than
those that have inherited Fc receptor alleles less activeat ADCC with IgG [68]. Analogous data have recently
been observed for treatment of NBL with tumor-spe-
cific mAb and GM-CSF [69].
ANTIBODY-MEDIATED ENHANCEMENT OF EFFECTOR-
CELL FUNCTION FOR TREATMENT OF NBL
If the activity of mAbs is mediated, at least in part,
through ADCC, then mechanisms to augment ADCC
by activating the effector function of cells mediating
ADCC should augment antitumor effects. Preclinical
studies have confirmed this by using IL-2 to augment
NK-mediated ADCC or GM-CSF to augment neu-
trophil/monocyte ADCC [65,66]. Cheung et al. [69]
have recently shown that patients receiving treatment
with an anit-GD2 mouse mAb (clone 3F8) together
with GM-CSF show a greater likelihood of disease
free survival if their neutrophil/macrophage Fc recep-
tor phenotype is of high affinity for the 3F8 molecule.
This same correlation was not observed when patients
were given 3F8 but not GM-CSF, suggesting that the
GM-CSF treatment was important for enabling neu-
trophil/monocyte mediated in vivo ADCC. In keeping
with this concept, the Children’s Oncology Group
(COG) is in the midst of a large Phase III trial for chil-
dren with high-risk NBL that have achieved CR by
multiagent induction chemotherapy with autologous
bone marrow transplant consolidation. They are being
randomized to cis retinoic acid alone versus cis retinoic
acid together with a chimeric anti-GD2 monoclonal
antibody (Ch14.18) together with GM-CSF and with
IL-2 [70]. Patients are still being accrued and the com-
parative analysis will be in several years prior to pro-
vide sufficient follow-up.
ANTIBODY CONJUGATES AND FUSION PROTEINS
To optimize direct antibody-mediated effects to-
gether with effector cell activation, Sondel and Gil-
lies [66] have created fusion proteins consisting of
tumor reactive mAbs genetically linked to human cy-
tokines such as IL-2. These fusion proteins have
been designated immunocytokines. The initially de-
scribed immunocytokine consists of the humanized
anti-GD2 molecule (Hu14.18) linked to human IL-
2 and designated Hu14.18-IL2 (Figure 5). This fu-
sion protein mediates striking antitumor effects
against GD2-positive malignancies in preclinical
mouse models with far greater efficacy than molar
equivalent amounts of IL-2, together with Hu14.18
mAb, given as separate reagents. Clinical Phase I
trials of this reagent in adults with melanoma and
children with neuroblastoma through the COG
are complete, and Phase II studies are near comple-
tion [71,72]. In vivo immune activation using surro-
gate endpoints have been observed. Other
conjugates include linking mAbs to radionuclides
to deliver ‘‘radioimmunotherapy.’’ This has been
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related to Rituximab. Other mAbs have been linked di-
rectly to toxins. Gemtuzumab is an anti-CD33 mono-
clonal that recognizes AML cells linked to the potent
toxin calicheamicin. This agent is U.S. Food and
Drug Administration (FDA) approved for its use in
treating adults with AML, and is currently being tested
through the COG for its potential use in children with
AML.
NOVEL ‘‘NONTUMOR’’ TARGETS FOR POTENTIAL CANCER
IMMUNOTHERAPY
Although most ongoing clinical testing involves
mAbs that recognize antigenic determinants selec-
tively expressed by tumor cells themselves, several
more recently described target antigens are found on
nontumor elements, yet may be appropriate targets
for mAb administration as cancer therapy. One main
category involves determinants selectively expressed
on the stroma of tumors in vivo. This can include
determinants selectively expressed by the stromal
fibroblasts found within tumors, which may have a dis-
tinct phenotype from fibroblasts in nonneoplastic
sites. Potentially more important are the pattern of
integrins and growth factor receptors expressed on
the neo angiogenic blood vessels found within the tu-
mor microenvironment. These express a variety of
growth factor receptors and integrin molecules (such
as VEGFR, and avb3 integrin) that are the targets of
mAbs currently in clinical trials. In this setting, the
tumor blood vessels and stroma are not neoplastic cells
themselves, but are the target for potentially destruc-
tive actions of mAbs directed against them [56].
Other distinct targets for cancer immunotherapy
include antigens that are not expressed on the tumor
Figure 5. Schematic of hu14.18-IL2 (EMD 273063) immunocyto-
kine linking GD21 tumor cells and IL-2R1 lymphocyte [75].cells or within the tumor microenvironment. These
are molecules that are expressed on immune cells
that downregulate the immune system. In particular,
T regulatory cells appear to inhibit antitumor immune
responses and, at least preclinically, there elimination
using monoclonal antibody can augment tumor reac-
tive immune responses. Somewhat analogously, the
CTLA4 molecule found on antigen-specific T cells
transmits an inhibitory signal to the T cells upon con-
tact with the appropriate costimulatory molecule on
target cells or APC. The use of an antagonistic anti-
CTLA4 antibody can block this immunosuppressive
signal. The result is a greater population of activated
tumor-specific lymphocytes. A side effect is the induc-
tion of autoimmunity with a wide variety of normal tis-
sue targets.
CLINICAL SETTING FOR TUMOR-REACTIVE mAbs
Although the striking success of the anti-CD20
mAb, Rituximab, includes activity in the face of
‘‘bulky, clinically evident’’ disease [73], most preclin-
ical trials of immunotherapy (including mAbs) dem-
onstrate the greatest and most long-lasting effects
are obtained when immunotherapies are applied in
the setting of MRD. Thus, clinical efficacy for
mAbs will likely require integrating antibody treat-
ment regimens into the standard multimodality ap-
proach toward management of children with cancers
[74]. The best timing for these treatments may be
influenced by the schedule required for remission in-
duction utilizing standard therapies, and the need to
retain or activate some degree of endogenous im-
mune function to facilitate the immune-mediated an-
titumor effects.
PROVIDING ANTIBODY RECOGNITION MECHANISMS TO
EFFECTOR CELLS
The most straightforward clinical application of
mAbs (or their genetic derivatives) involves their in-
travenous administration directly to patients as ‘‘anti-
tumor drugs’’ with their storage and administration
by a standard hospital/clinic pharmacy. More techni-
cally complex, but novel approaches, have involved ge-
netically engineering the antigen binding site of tumor
reactive mAbs onto triggering structures that can be
specifically transfected into T cells or into NK cells.
Such an approach confers upon the transfected effector
cells tumor specific ‘‘artificial receptors’’ that utilize
antibody recognition of the tumor antigens. Preclini-
cal testing of these concepts, using transfected T or
NK cells can demonstrate efficacy; clinical testing of
such genetically engineered cells, including testing in
the pediatric setting, is underway.
The capability to screen potentially thousands
of tumor-reactive mAbs to identify the targets of great-
est utility, coupled with genetic engineering of these
Immunotherapy for Pediatric Cancer 41molecules to optimize their clinical efficacy has already
resulted in several cancer selective mAbs being ap-
proved by the FDA for standard treatment of certain
malignancies. Ongoing testing is underway in the pe-
diatric setting, particularly for lymphoid and myeloid
malignancies, as well as NBL. Integrating these treat-
ments into standard multimodality therapy will re-
quire close analysis of timing and potential
synergistic versus antagonistic effects on the mecha-
nisms involved, yet will likely result in combined reg-
imens with greater efficacy.
CONCLUSION
Immunotherapy for pediatric cancers has been
more than 85 years in the making if one starts in
1922 with Dr. William Coley, at the Sloan-Kettering
Institute, who demonstrated that the growth of some
cancers can be controlled, and a few advanced cancers
cured, with injections of a mixed vaccine of streptococ-
cal and staphylococcal bacteria (Coley’s toxin). Pediat-
ric oncologists recognize that although the application
of current conventional cytotoxic agents may be effec-
tive in the short run, they lead to unacceptable toxic-
ities in the long run. As a result, centers caring for
children with cancer are testing immune-based thera-
pies since these biologics are exquisitely capable of
differentiating normal from malignant cells. As
demonstrated in this review, immuno-therapies based
on T cells, NK cells, and mAbs, are already being tai-
lored for the treatment of pediatric malignancies.
Thus, after decades in development, immunotherapy
is set to enter the mainstream of pediatric oncology
practice as an adjunct to other multimodal therapies.
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